Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of 0.3% Roflumilast Foam (ZORYVE) in Seborrheic Dermatitis
CTR20262831Phase 3Active
- Sponsor
- Arcutis Biotherapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roflumilast in seborrheic dermatitis (SD), sponsored by Arcutis Biotherapeutics. Started Aug 2026; status: active.
02
Drugs
roflumilast
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on CTR20262831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262831.